GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
To determine the extent to which the effects of treatment with LAF237 100 mg QD on glucagon
secretion are mediated by Glucagon-like-peptide 1 (GLP-1) in type 2 diabetic patients and
healthy subjects.